Clinical Trial Update: Oral AMXT 1501 Dicaprate in Combination With IV DFMO [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of oral AMXT 1501 dicaprate in combination with IV DFMO has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Diffuse Intrinsic Pontine Glioma
• Diffuse Midline Glioma
• Endometrial Cancer
• Esophageal Cancer
• Gastric Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer

Drugs mentioned

• AMXT 1501 dicaprate (AMXT-1501 dicaprate)
• DFMO (difluoromethylornithine)

Snippet

Sponsor: Aminex Therapeutics, Inc. | Conditions: Cancer, Solid Tumor | Phase 1, Phase 2 | Status: TERMINATED